Biogen Idec Seeks Oncology Pipeline Boost Through Acquisition

Merger with Conforma Therapeutics, valued at up to $250 mil., brings Biogen Idec a stable of developmental heat shock protein inhibitors.

More from Archive

More from Pink Sheet